Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Podcasts|November 20, 2026 (Updated: November 19, 2026)

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global

Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today: a bispecific aimed at a target that has long been held back by safety problems, a phase 2 miss that clarifies the role of mast cells, and a GLP-1 deal that reaches beyond China.

First, Leads Biolabs detailed long-term data for opamtistomig, a PD-L1/4-1BB bispecific antibody. It binds PD-L1 with high affinity and 4-1BB with very low affinity, which the company says confines 4-1BB activation to the tumor. The design aims to avoid the liver toxicity that has held back 4-1BB agonists. In its pivotal study in extrapulmonary neuroendocrine carcinoma, median overall survival was 8.7 months versus about 3 to 4 months in historical controls. The company says it plans to combine the bispecific with ADCs starting in 2027.

Next, Celldex Therapeutics is ending development of barzolvolimab in atopic dermatitis. The anti-KIT antibody depletes mast cells, but neither dose significantly reduced itch versus placebo at week 16. Celldex concluded that mast cells contribute to atopic dermatitis but are not a primary driver. Development continues in chronic urticarias, and Celldex plans a BLA submission in chronic spontaneous urticaria in 2027.

And finally, Innogen has licensed efsubaglutide alfa to Abu Dhabi-based Arcera Life Sciences. The deal covers selected countries across Africa, Eastern Europe, Latin America, and the Middle East. The drug fuses a GLP-1 analogue with an IgG Fc fragment and is already approved for type 2 diabetes in China. Innogen receives $38 million in upfront and near-term payments, and the deal’s total potential value tops $1 billion. www.biopharminternational.com

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Engineering around toxicity: Opamtistomig tests whether affinity tuning can make 4-1BB a workable cancer target, though its efficacy data so far are measured against historical rather than randomized controls.
  • Mechanism lessons: Celldex’s two discontinuations suggest mast cells aren’t the key driver in itch-dominant skin diseases, but they matter in urticaria.
  • Global reach: Chinese GLP-1 developers are licensing their drugs into emerging markets as well as through Western partners.

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.